10 Dyax Corp. Analyst Ratings, Earnings, Dividends and Insider Trades | $DYAX | NASDAQ:DYAX | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Dyax Corp. Company Profile (NASDAQ:DYAX) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Dyax Corp. (NASDAQ:DYAX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 1 Hold Rating(s), 3 Buy Rating(s)Consensus Rating:Buy (Score: 2.75)Consensus Price Target: $12.40 (22.17% upside) Analysts' Ratings History for Dyax Corp. (NASDAQ:DYAX) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/28/2014OppenheimerInitiated CoverageOutperform$14.00View 2/27/2014Leerink SwannDowngradeOutperform -> Market PerformView 2/26/2014WedbushBoost Price Target$11.00 -> $14.00View 2/26/2014Cowen and CompanyBoost Price Target$10.00 -> $12.50View 2/26/2014Leerink SwannDowngradeOutperform -> Market Perform$8.00 -> $12.00View 2/18/2014Needham & CompanyBoost Price TargetBuy$7.50 -> $13.00View 1/13/2014WedbushInitiated CoverageOutperform$11.00View 10/23/2013Leerink SwannBoost Price TargetOutperform$7.00 -> $8.00View 10/23/2013Cowen and CompanyBoost Price TargetOutperform$7.00 -> $7.50View 10/16/2013Jefferies GroupBoost Price TargetBuy$5.00 -> $8.50View 9/16/2013Needham & CompanyReiterated RatingBuy$5.00View 9/16/2013Leerink SwannBoost Price TargetOutperform$5.00 -> $7.00View 7/25/2013Needham & CompanyBoost Price TargetBuy$4.00 -> $5.00View 4/26/2013Needham & CompanyLower Price TargetBuy$5.00 -> $4.00View 4/26/2013Leerink SwannLower Price TargetOutperform$6.00 -> $5.00View 4/26/2013Jefferies GroupLower Price TargetBuy$6.00 -> $5.00View 3/5/2013Jefferies GroupInitiated CoverageBuy$6.00View 11/16/2012JMP SecuritiesReiterated RatingOutperform$6.00View 10/25/2012Needham & CompanyReiterated RatingBuyView 7/20/2012Needham & CompanyReiterated RatingBuyView 6/20/2012Needham & CompanyInitiated CoverageBuy$3.50View 5/29/2012Leerink SwannUpgradeMarket Perform -> OutperformView (Data available from 3/12/2012 forward) Earnings History for Dyax Corp. (NASDAQ:DYAX)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/28/2014Q413($0.04)($0.02)$15.84 million$16.90 millionViewN/AView 10/22/2013Q313($0.05)($0.06)$14.80 million$13.70 millionViewN/AView (Data available from 1/1/2011 forward) Dividend History for Dyax Corp. (NASDAQ:DYAX)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Dyax Corp. (NASDAQ:DYAX)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare3/5/2014Henry BlairDirectorSell150,000$10.46$1,569,000.00View 3/3/2014Andrew AsheEVPSell30,000$10.00$300,000.00View 3/3/2014Burt AdelmanCMOSell55,000$9.68$532,400.00View 2/26/2014Andrew AsheVPSell2,723$10.10$27,502.30View 12/5/2013Thomas KempnerDirectorSell400,000$8.37$3,348,000.00View 8/13/2013Andrew AsheVPSell32,500$4.30$139,750.00View 5/16/2013Marc D KozinDirectorBuy22,971$2.46$56,508.66View 2/25/2013George V MigauskyCFOSell4,275$3.28$14,022.00View 2/25/2013Ivana MagovcevicCOOSell4,015$3.24$13,008.60View (Data available from 1/1/2013 forward) About Dyax Corp. Dyax Corp. (Dyax), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program. It is focused on identifying and developing treatments for patients who experience plasma kallikrein (bradykinin) mediated angioedema. The principal focus of Dyax is to identify, develop and commercialize treatments for conditions identified as plasma kallikrein (bradykinin) mediated angioedema, including hereditary angioedema (HAE), ACE inhibitor-induced angioedema (ACEI-AE) and angioedema of unknown origin, or idiopathic angioedema. It developed KALBITOR (ecallantide) on its own in the United States for the treatment of acute attacks of HAE. Outside of the United States, it has established partnerships to obtain regulatory approval for and commercialize KALBITOR in certain markets and it is evaluating opportunities in others. It leverages its phage display technology through the Licensing and Funded Research Program (LFRP). Headlines: (2/28) Dyax Corp. Announces Fourth Quarter and Full Year 2013 Financial Results (2/26) Dyax Corp. to Participate in the 2014 Cowen and Company 34th Annual Health Care Conference (2/25) Dyax Announces Positive Results from Phase 1a Clinical Trial of DX-2930 (2/27) Dyax Corp. (DYAX) Soars: Stock Rises 6.7% (2/13) Dyax Corp. to Host Fourth Quarter and Year End 2013 Earnings Call and Webcast (2/26) Press Release (3/3) Dyax results revenue beat estimates (2/28) Dyax reports total revenues of $16.9 million for fourth quarter 2013 Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: DYAX CUSIP: 26746E10 Key Metrics: Previous Close: $10.1450 Day Moving Average: $9.2903200 Day Moving Average: $7.689 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $1.280BCurrent Quarter EPS Consensus Estimate: $-0.22 EPS Additional Links: View DYAX on Google FinanceView DYAX on Yahoo FinanceView DYAX's Company Profile on ReutersSearch for Dyax Corp. on Google Dyax Corp. (NASDAQ:DYAX) Chart for Wednesday, March, 12, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.